Brucellosis Treatment Market Size, Share, and Growth Forecast 2026 - 2033

The global brucellosis treatment market size is likely to be valued at US$512.7 million in 2026 and is estimated to reach US$845 million by 2033, growing at a CAGR of 7.4% during the forecast period from 2026 to 2033, driven by the rising incidence of zoonotic transmission from livestock to humans, mainly through infected small ruminants and unpasteurized dairy products. Surging government investment in brucellosis vaccination, surveillance, and laboratory testing is also improving disease detection and treatment uptake.

Driver - High Livestock Exposure to Increase Human Infections

Brucellosis continues to expand where people have frequent contact with cattle, sheep, goats, and other infected animals. Brucella melitensis is particularly important as small-ruminant farming creates repeated exposure for farmers, veterinarians, slaughterhouse workers, and dairy handlers. Raw milk and fresh dairy products can also transmit the infection.

This keeps antibiotic treatment demand high in endemic countries. The WHO identifies direct animal contact and consumption of contaminated animal products as major transmission routes. The risk is especially relevant in parts of Asia and the Middle East & Africa, where livestock production remains closely linked to household income and food supply.

Better Surveillance to Bring More Cases into Treatment

Strong surveillance is increasing the identification of infections that were previously missed or misclassified. China provides a clear example. Reported human brucellosis cases increased from 45,046 in 2019 to 70,439 in 2023, with cases increasingly reported outside traditional northern endemic areas.

China is also using genomic analysis and mathematical modelling to understand transmission patterns. India is following a similar One Health approach through livestock vaccination, disease monitoring, and laboratory testing. Better detection expands the pool of patients requiring antibiotic therapy and follow-up care.

Restraint - Persistent Relapse May Make Treatment Longer and Highly Difficult

Brucellosis can persist inside cells, making complete eradication difficult and increasing the risk of relapse when treatment is inadequate or interrupted. The CDC notes that relapse can occur because of poor adherence, monotherapy, or insufficient treatment duration. Recent clinical evidence illustrates the challenge.

A 2025 study of 581 patients in Xinjiang reported 45 relapses during follow-up despite most patients receiving antibiotic treatment. Long combination regimens also create adherence and tolerability challenges. These factors are anticipated to discourage patients from completing therapy and complicate management of chronic or focal disease. Complications such as spondylitis, neurobrucellosis, and endocarditis may require long or modified regimens, increasing clinical complexity.

Opportunity - Human Vaccine Research to Open a New Treatment-adjacent Market

One of the key unmet needs is the absence of a licensed human brucellosis vaccine. This leaves prevention heavily dependent on controlling infection in animals and reducing human exposure. Researchers are therefore exploring recombinant proteins, viral vectors, DNA vaccines, and mRNA-based approaches.

A 2025 study evaluated Omp25 and BP26 mRNA candidates against B. abortus, showing the shift toward non-live vaccine technologies. These candidates are still experimental, so they should not be described as commercial human vaccines. However, successful clinical development could significantly change the prevention landscape.

Simplified Antibiotic Regimens to Address Adherence Problems

Conventional treatment often requires multiple antibiotics for several weeks. Long treatment schedules can create adherence problems and adverse effects. This has created an opportunity for therapies that can maintain efficacy with fewer drugs or simpler dosing.

A 2026 multicenter randomized trial in China compared sitafloxacin monotherapy with doxycycline plus rifampicin in adults with acute uncomplicated brucellosis. Such studies are important because a successful simplified regimen could make outpatient treatment easier and potentially improve completion rates.

Pathogen Species Insights

Brucella melitensis is predicted to lead with a share of about 43.2% in 2026, as it is strongly associated with sheep and goats, which are important reservoirs in endemic regions, and it is also the most prevalent Brucella species causing human brucellosis worldwide. Its importance is reinforced by its ability to spread to humans through raw milk, fresh cheese, direct animal contact, and occupational exposure. WOAH identifies B. melitensis as the main Brucella species infecting sheep and goats, while recent studies continue to document its circulation in China, India, and the Middle East.

Brucella abortus is estimated to be the fastest-growing source over the forecast period, as cattle remain an important reservoir and bovine brucellosis continues to require large-scale vaccination, surveillance, and testing programs. The continued use of S19 and RB51 vaccines and renewed research into improved B. abortus vaccines also supports ongoing demand for prevention and control products.

Diagnosis Insights

Serological tests are anticipated to dominate with a share of around 48.5% in 2026, as they are fast, comparatively inexpensive, widely available, and easier to deploy than bacterial culture or molecular testing, mainly in endemic and resource-limited settings. The World Health Organization (WHO) and the World Organization for Animal Health (WOAH) both recognize serological testing as an important part of brucellosis surveillance and diagnosis. A 2025 review also found that Rose Bengal, serum agglutination, ELISA, and related antibody-based methods remain central to brucellosis diagnosis, although confirmation can require culture or molecular testing.

Advanced imaging modalities (MRI/CT) are expected to be the fastest-growing application over the forecast period. Their role is growing because they identify focal complications such as spondylitis, spondylodiscitis, osteomyelitis, abscesses, and neurological involvement. This is important because treatment becomes longer and more complex when brucellosis spreads to bones, joints, the spine, or the nervous system. The CDC specifically identifies spondylitis and neurobrucellosis as complicated forms requiring treatment adjustments.

Asia Pacific Brucellosis Treatment Market Trends

Asia Pacific is anticipated to lead worldwide in 2026 with a share of around 45.7%, as China and India combine large livestock populations with persistent human and animal brucellosis transmission. WOAH states that the incidence is particularly high in China and India and that Central and Southwest Asia are experiencing some of the greatest increases in cases. China provides a particularly strong example. China CDC reported that human cases increased from 45,046 in 2019 to 70,439 in 2023, with major concentrations in Inner Mongolia, Xinjiang, and Shanxi.

China Brucellosis Treatment Market Trends

China will likely lead in Asia Pacific in 2026 with a share of about 32.7%, as brucellosis has expanded beyond traditional northern endemic areas, while intensive livestock production and animal movement continue to create transmission risks. China CDC identified an increase in southern provinces as well, with reported southern cases rising from 2,036 in 2019 to 5,128 in 2023. Recent Chinese research is also expanding into genomic surveillance, mathematical modelling, and alternative antibiotic regimens, strengthening the country's brucellosis treatment and diagnostic network.

India Brucellosis Treatment Market Trends

In 2026, India is projected to account for a share of just about 20.4% in Asia Pacific, as it has a large livestock base and continues to invest in organized brucellosis surveillance and vaccination. Under the national program, brucellosis vaccination is provided with central government support, and the government reported millions of vaccinations across states. The market is further supported by clinical and genomic research. A 2025 Indian study characterized B. melitensis ST8 isolates and examined their virulence-related genes, showing the increasing role of genomic surveillance in understanding local strains.

Middle East and Africa Brucellosis Treatment Market Trends

The Middle East and Africa will likely be the fastest-growing region over the forecast period with a share of roughly 26.5% in 2026 globally, because brucellosis remains endemic, livestock exposure is widespread, and consumption of unpasteurized animal products remains an important transmission route. WOAH identifies the Middle East and sub-Saharan Africa among the regions with the highest incidence. The Middle East also has a growing focus on laboratory capacity, surveillance, and One Health programs. WOAH notes that the disease remains underdiagnosed and underreported in parts of the region, creating additional room for testing and treatment demand as detection improves.

Kuwait Brucellosis Treatment Market Trends

Kuwait is predicted to register a substantial share of approximately 38.8% in 2026 in the Middle East and Africa, as it has a long-established brucellosis burden, with both human disease and animal reservoirs contributing to demand for diagnosis and treatment. The country has also historically used serological testing extensively, while PCR-based approaches have been investigated for more specific detection. Recent regional evidence continues to place Kuwait within the Middle Eastern brucellosis risk landscape.

Qatar Brucellosis Treatment Market Trends

A share of nearly 15.4% is predicted to be held by Qatar in 2026 in the Middle East and Africa. It has a meaningful clinical burden despite its relatively small population. A study of 346 human cases found that 21.4% had focal disease, with osteoarticular involvement the most common focal presentation, while doxycycline combined with rifampicin or gentamicin was commonly used. This makes Qatar particularly relevant for demand for prolonged antibiotic therapy, specialist management, and imaging of complicated cases.

North America Brucellosis Treatment Market Trends

North America is predicted to showcase steady growth in 2026 globally with a share of approximately 13.2%, because domestic brucellosis control programs have greatly reduced transmission in livestock. However, residual wildlife reservoirs, imported infections, occupational exposure, and consumption of unpasteurized products continue to generate cases.

U.S. Brucellosis Treatment Market Trends

A share of nearly 56.9% is expected to be held by the U.S. in 2026 in North America. CDC recorded 1,796 confirmed and probable cases reported during 2010-2024, with 71-165 cases reported annually. California, Texas, and Florida accounted for the largest numbers. The U.S. is also strengthening surveillance. In June 2026, CDC published its first major national brucellosis surveillance summary since adoption of the 2010 case definition. This can improve case identification and clinical awareness even when underlying transmission remains comparatively low.

The global brucellosis treatment market is fragmented, with no single company dominating because human treatment mainly relies on established generic antibiotics The competitive environment is different from that of a conventional branded-drug market. Human brucellosis treatment is still centered on established combinations such as doxycycline with rifampicin. Aminoglycosides and fluoroquinolones are used in selected cases. The CDC's 2026 U.S. surveillance report confirms that doxycycline and rifampin remain the most frequently reported antimicrobials.

It limits the opportunity for companies selling conventional antibiotics to differentiate through new branded therapies. The more active competitive areas are diagnostics, veterinary vaccines, molecular testing, and improved treatment regimens. Companies that participate in broad infectious-disease portfolios can hence compete indirectly through antibiotic supply, laboratory testing, and animal-health products. The absence of an approved human brucellosis vaccine also leaves room for new vaccine technologies.

Key Industry Developments:

• In July 2026, researchers reported A19Δbpe275, a modified live-attenuated vaccine candidate designed to improve safety while retaining protection against brucellosis. The study, published in npj Vaccines, adds to the expanding pipeline of next-generation veterinary vaccine candidates.
• In June 2026, a multicenter randomized trial published in The Lancet Regional Health - Western Pacific compared sitafloxacin monotherapy with doxycycline plus rifampicin for acute uncomplicated human brucellosis. The trial enrolled 238 adults at three Chinese hospitals and followed participants for 12 months. This is one of the more relevant recent developments because it directly evaluates whether a simpler treatment approach can compete with the established combination regimen.
• In May 2026, the World Organization for Animal Health conducted its second regional training workshop on brucellosis diagnosis in Beijing with China's Institute of Veterinary Drug Control and Ministry of Agriculture and Rural Affairs. The initiative reflects the growing emphasis on laboratory capacity and standardized diagnosis across Asia.